Kite, Juno, and BlueBird will give updates on T-cell therapies.
Drug will also be available to children via Cancer Drugs Fund.
Swiss pharma also aims for new CAR-T therapy indication.
MSD keeps pressure on BMS with EU classical Hodgkin lymphoma indication.
Merck’s rival Keytruda gets new US indication.
The FDA has accepted Celgene’s filing for enasidenib.
Roche’s top seller faces rival four years after patent expiry
Antibody-drug conjugate with FDA gets six-month review.